Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
26-29 March, 2025
Not Confirmed
Not Confirmed
27-29 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
26-29 March, 2025
Industry Trade Show
Not Confirmed
27-29 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
06 Mar 2025
// BIOSPACE
https://www.biospace.com/business/mercks-injectable-keytruda-plans-create-legal-dispute-with-halozyme-wsj
26 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-td-cowen-45th-annual-healthcare-conference-302385786.html
18 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial-guidance-for-royalty-revenue-adjusted-ebitda-and-non-gaap-diluted-eps-302379289.html
04 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-302367381.html
06 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/halozyme-to-host-investor-conference-call-to-provide-updated-2025-financial-guidance-302342725.html
30 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/halozyme-announces-argenxs-vydura-with-enhanze-was-granted-regulatory-approval-in-japan-for-chronic-inflammatory-demyelinating-polyneuropathy-302340000.html
Inspections and registrations
ABOUT THIS PAGE
Halozyme Therapeutics is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of ENHANZE DRUG PRODUCT bulk with DMF offered by Halozyme Therapeutics